“PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s237. doi:10.25251/skin.7.supp.237.